CD274 and cancer: On these bases, the proinflammatory and ERS induced by the HLA-B*35 allele as well as the Th2-promoting ability of DRB1*11 might explain the increased rate of IRPs in cancer patients receiving PD-1/PD-L1 immune checkpoint inhibitors.